Literature DB >> 18470756

Sample size calculations in thorough QT studies.

Lu Zhang1, Alex Dmitrienko, George Luta.   

Abstract

An analysis of QTc data collected in four thorough QT studies conducted at Eli Lilly and Company was performed to estimate the variability of the QTc interval and to calculate the variance components related to time-to-time, day-to-day variability, etc. The results were used to develop a sample size calculation framework that enables clinical trial researchers to account for key features of their thorough QT studies, including study design (parallel and crossover designs), number of ECG replicates, number of post-baseline ECG recordings, and subject population (based on subject gender and age). The sample size calculation framework is illustrated using several popular study designs.

Mesh:

Substances:

Year:  2008        PMID: 18470756     DOI: 10.1080/10543400801993002

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Concentration-QTc analysis with two or more correlated baselines.

Authors:  Yasushi Orihashi; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-12       Impact factor: 2.745

2.  Concentration-QTc analysis for single arm studies.

Authors:  Yasushi Orihashi; Shoichi Ohwada; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-29       Impact factor: 2.745

3.  Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Authors:  Johanna C Bendell; Manish R Patel; Kenichiro Yoshida; Jabed Seraj; Racquel Weaver; Charlotte Lemech; Thomas G Todaro; Shubham Pant; Hendrik-Tobias Arkenau
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-05       Impact factor: 3.333

4.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.